{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:09:56Z","timestamp":1794330596326,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lupus nephritis (LN) is a severe consequence of systemic lupus erythematosus (SLE) that affects approximately 40% of patients. Pathogenic immune complexes that are characteristic of LN deposit in the kidney and activate immune mediated pathways including the complement system. Complete remission rates in LN are approximately 44% highlighting the need for new treatment strategies in these patients. Eculizumab is a fully humanised IgG2\/IgG4 monoclonal antibody directed at C5 and thus prevents the formation of the terminal complement complex. Eculizumab is successfully used in atypical haemolytic uraemic syndrome (aHUS) and paroxysomal nocturnal haemoglobinuria (PNH) but it is not standardly used in LN. The aim of this project was to determine whether there is any role for eculizumab as adjunctive therapy in LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a predefined search strategy on Ovid MEDLINE and EMBASE the literature was reviewed systematically to identify studies in which eculizumab had been used to treat patients with SLE. All patients were included that were treated with complement inhibitors. Favourable outcome in this study was defined as resolution of symptoms that led to treatment, discharge from hospital or recovery of renal function. Patients were excluded if there was no outcome data or if complement inhibition was unrelated to their SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 192 abstracts screened, 14 articles were identified, involving 30 patients. All SLE patients administered eculizumab were treated for thrombotic microangiopathy (TMA) secondary to LN diagnosed either histologically (66%) or as part of a diagnosis of aHUS (73%). 93% of patients had a favourable outcome in response to eculizumab treatment, of which 46% had a favourable outcome and successfully stopped treatment without relapse in symptoms during a median follow up of 7\u2009months. Three patients (10%) reported adverse outcomes related to eculizumab therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Scientific evidence supports the involvement of complement in the pathogenesis of LN however the role of complement inhibition in clinical practice is limited to those with TMA features. This systematic review showed that in cases of LN complicated with TMA, eculizumab seems to be a very efficacious therapy. Further evidence is required to determine whether patients with refractory LN may benefit from adjunctive complement inhibition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-01888-5","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T14:59:53Z","timestamp":1593529193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-2297","authenticated-orcid":false,"given":"Rachael D.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Bannerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Oni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"1888_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/08916930400022616","volume":"38","author":"P Riboldi","year":"2005","unstructured":"Riboldi P, Gerosa M, Moroni G, et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity. 2005;38:39\u201345. https:\/\/doi.org\/10.1080\/08916930400022616.","journal-title":"Autoimmunity"},{"key":"1888_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1681\/ASN.2006090992","volume":"18","author":"SM Korbet","year":"2007","unstructured":"Korbet SM, Schwartz MM, Evans J, et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18:244\u201354. https:\/\/doi.org\/10.1681\/ASN.2006090992.","journal-title":"J Am Soc Nephrol"},{"key":"1888_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.kint.2016.03.042","volume":"90","author":"PJ Hoover","year":"2016","unstructured":"Hoover PJ, Costenbader KH. Insights into the epidemiology and Management of Lupus Nephritis from the U.S. Rheumatologist\u2019s perspective. Kidney Int. 2016;90:487\u201392. https:\/\/doi.org\/10.1016\/j.kint.2016.03.042.","journal-title":"Kidney Int"},{"key":"1888_CR4","doi-asserted-by":"publisher","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782. 2012\/08\/02. DOI: https:\/\/doi.org\/10.1136\/annrheumdis-2012-201940.","DOI":"10.1136\/annrheumdis-2012-201940"},{"key":"1888_CR5","doi-asserted-by":"publisher","unstructured":"Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 2017; 76: 1965-1973. 2017\/09\/08. DOI: https:\/\/doi.org\/10.1136\/annrheumdis-2017-211898.","DOI":"10.1136\/annrheumdis-2017-211898"},{"key":"1888_CR6","doi-asserted-by":"publisher","unstructured":"Zampeli E, Klinman DM, Gershwin ME, et al. A comprehensive evaluation for the treatment of lupus nephritis. J Autoimmun 2017; 78: 1\u201310. 2017\/01\/14. DOI: https:\/\/doi.org\/10.1016\/j.jaut.2016.12.011.","DOI":"10.1016\/j.jaut.2016.12.011"},{"key":"1888_CR7","doi-asserted-by":"publisher","unstructured":"Davidson A. What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol 2016; 12: 143\u2013153. 2015\/11\/19. DOI: https:\/\/doi.org\/10.1038\/nrrheum.2015.159.","DOI":"10.1038\/nrrheum.2015.159"},{"key":"1888_CR8","doi-asserted-by":"publisher","unstructured":"Wang H, Xu J, Zhang X, et al. Tubular basement membrane immune complex deposition is associated with activity and progression of lupus nephritis: a large multicenter Chinese study. Lupus 2018; 27: 545\u2013555. 2017\/09\/29. DOI: https:\/\/doi.org\/10.1177\/0961203317732407.","DOI":"10.1177\/0961203317732407"},{"key":"1888_CR9","doi-asserted-by":"publisher","unstructured":"Sugisaki T and Takase S. Composition of immune deposits present in glomeruli of NZB\/W F1 mice. Clin Immunol Immunopathol 1991; 61: 296\u2013308. 1991\/12\/01. DOI: https:\/\/doi.org\/10.1016\/s0090-1229(05)80002-9.","DOI":"10.1016\/s0090-1229(05)80002-9"},{"key":"1888_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"1888_CR11","doi-asserted-by":"publisher","unstructured":"Lansigan F, Isufi I and Tagoe CE. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Rheumatology (Oxford) 2011; 50: 824\u2013829. 2010\/12\/15. DOI: https:\/\/doi.org\/10.1093\/rheumatology\/keq395.","DOI":"10.1093\/rheumatology\/keq395"},{"key":"1888_CR12","doi-asserted-by":"publisher","unstructured":"Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013; 15: R12. 2013\/01\/17. DOI: https:\/\/doi.org\/10.1186\/ar4142.","DOI":"10.1186\/ar4142"},{"key":"1888_CR13","doi-asserted-by":"publisher","unstructured":"Ricklin D, Reis ES and Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol 2016; 12: 383\u2013401. 2016\/05\/24. DOI: https:\/\/doi.org\/10.1038\/nrneph.2016.70.","DOI":"10.1038\/nrneph.2016.70"},{"key":"1888_CR14","doi-asserted-by":"publisher","unstructured":"Costa-Reis P and Sullivan KE. Monogenic lupus: it\u2019s all new! Curr Opin Immunol 2017; 49: 87\u201395. 2017\/11\/04. DOI: https:\/\/doi.org\/10.1016\/j.coi.2017.10.008.","DOI":"10.1016\/j.coi.2017.10.008"},{"key":"1888_CR15","doi-asserted-by":"publisher","unstructured":"Pereira KM, Faria AG, Liphaus BL, et al. Low C4, C4A and C4B gene copy numbers are stronger risk factors for juvenile-onset than for adult-onset systemic lupus erythematosus. Rheumatology (Oxford) 2016; 55: 869\u2013873. 2016\/01\/24. DOI: https:\/\/doi.org\/10.1093\/rheumatology\/kev436.","DOI":"10.1093\/rheumatology\/kev436"},{"key":"1888_CR16","doi-asserted-by":"publisher","unstructured":"Leffler J, Bengtsson AA and Blom AM. The complement system in systemic lupus erythematosus: an update 2014. DOI: https:\/\/doi.org\/10.1136\/annrheumdis-2014-205287.","DOI":"10.1136\/annrheumdis-2014-205287"},{"key":"1888_CR17","doi-asserted-by":"publisher","unstructured":"Chen M, Daha MR and Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010; 34: J276\u2013J286. 2009\/12\/17. DOI: https:\/\/doi.org\/10.1016\/j.jaut.2009.11.014.","DOI":"10.1016\/j.jaut.2009.11.014"},{"key":"1888_CR18","doi-asserted-by":"publisher","unstructured":"Song D, Guo WY, Wang FM, et al. Complement Alternative Pathways Activation in Patients With Lupus Nephritis. Am J Med Sci 2017; 353: 247\u2013257. 2017\/03\/07. DOI: https:\/\/doi.org\/10.1016\/j.amjms.2017.01.005.","DOI":"10.1016\/j.amjms.2017.01.005"},{"key":"1888_CR19","doi-asserted-by":"publisher","unstructured":"Mizuno M, Suzuki Y and Ito Y. Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology. Clin Exp Nephrol 2018; 22: 3\u201314. 2017\/03\/28. DOI: https:\/\/doi.org\/10.1007\/s10157-017-1405-x.","DOI":"10.1007\/s10157-017-1405-x"},{"key":"1888_CR20","unstructured":"Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs 2002; 3: 1017\u20131023. 2002\/08\/21."},{"key":"1888_CR21","doi-asserted-by":"crossref","unstructured":"Cavero T, Rabasco C, L\u00f3pez A, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017:466\u201374.","DOI":"10.1093\/ndt\/gfw453"},{"key":"1888_CR22","doi-asserted-by":"publisher","unstructured":"Socie G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 2019; 185: 297\u2013310. 2019\/02\/16. DOI: https:\/\/doi.org\/10.1111\/bjh.15790.","DOI":"10.1111\/bjh.15790"},{"key":"1888_CR23","doi-asserted-by":"publisher","unstructured":"Rizk DV, Maillard N, Julian BA, et al. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy. Front Immunol 2019; 10: 504. 2019\/04\/04. DOI: https:\/\/doi.org\/10.3389\/fimmu.2019.00504.","DOI":"10.3389\/fimmu.2019.00504"},{"key":"1888_CR24","doi-asserted-by":"publisher","unstructured":"Walsh PR and Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 2018; 103: 285\u2013291. 2017\/09\/14. DOI: https:\/\/doi.org\/10.1136\/archdischild-2016-311377.","DOI":"10.1136\/archdischild-2016-311377"},{"key":"1888_CR25","doi-asserted-by":"publisher","unstructured":"Khandelwal A, Wright JK, Pavenski K, et al. Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab. CMAJ 2017; 189: E1558-e1560. 2017\/12\/20. DOI: https:\/\/doi.org\/10.1503\/cmaj.170508.","DOI":"10.1503\/cmaj.170508"},{"key":"1888_CR26","doi-asserted-by":"crossref","unstructured":"Dayanand S, Sclair S, Enrico S. An unusual case of gastrointestinal bleeding that resolved with eculizumab infusion. Am J Gastroenterol. 2014;109.","DOI":"10.14309\/00000434-201410002-01155"},{"key":"1888_CR27","doi-asserted-by":"publisher","unstructured":"Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum 2018 2019\/01\/02. DOI: https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.005.","DOI":"10.1016\/j.semarthrit.2018.11.005"},{"key":"1888_CR28","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1182\/blood-2017-02-768234","volume":"130","author":"M Park","year":"2017","unstructured":"Park M, Weitz I. Effective treatment of thrombotic microangiopathy associated with lupus nephritis with eculizumab: a series of 8 cases. Blood. 2017;130:1043.","journal-title":"Blood"},{"key":"1888_CR29","doi-asserted-by":"publisher","unstructured":"De Holanda MI, Porto LC, Wagner T, et al. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol 2017; 36: 2859\u20132867. 2017\/09\/15. DOI: https:\/\/doi.org\/10.1007\/s10067-017-3823-2.","DOI":"10.1007\/s10067-017-3823-2"},{"key":"1888_CR30","doi-asserted-by":"publisher","unstructured":"Geethakumari PR, Mille P, Gulati R, et al. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome. Transfus Apher Sci 2017; 56: 400\u2013403. 2017\/04\/22. DOI: https:\/\/doi.org\/10.1016\/j.transci.2017.02.007.","DOI":"10.1016\/j.transci.2017.02.007"},{"key":"1888_CR31","unstructured":"Sarkissian S. Successful treatment of acute renal failure in patient with active lupus nephritis and atypical hemolytic uremic syndrome. J Investig Med. 2016;64."},{"key":"1888_CR32","doi-asserted-by":"publisher","unstructured":"Raufi AG, Scott S, Darwish O, et al. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep 2016; 8: 6625. 2016\/10\/27. DOI: https:\/\/doi.org\/10.4081\/hr.2016.6625.","DOI":"10.4081\/hr.2016.6625"},{"key":"1888_CR33","doi-asserted-by":"publisher","unstructured":"Bermea RS, Sharma N, Cohen K, et al. Use of Eculizumab in Atypical Hemolytic Uremic Syndrome, Complicating Systemic Lupus Erythematosus. J Clin Rheumatol 2016; 22: 320\u2013323. 2016\/08\/25. DOI: https:\/\/doi.org\/10.1097\/rhu.0000000000000423.","DOI":"10.1097\/rhu.0000000000000423"},{"key":"1888_CR34","doi-asserted-by":"crossref","unstructured":"Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). Engl. 2015:2286\u20138.","DOI":"10.1093\/rheumatology\/kev307"},{"key":"1888_CR35","doi-asserted-by":"publisher","unstructured":"El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015; 65: 127\u2013130. 2014\/12\/03. DOI: https:\/\/doi.org\/10.1053\/j.ajkd.2014.07.031.","DOI":"10.1053\/j.ajkd.2014.07.031"},{"key":"1888_CR36","doi-asserted-by":"publisher","unstructured":"Coppo R, Peruzzi L, Amore A, et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015; 30: 167\u2013172. 2014\/09\/01. DOI: https:\/\/doi.org\/10.1007\/s00467-014-2944-y.","DOI":"10.1007\/s00467-014-2944-y"},{"key":"1888_CR37","doi-asserted-by":"publisher","unstructured":"Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 2014; 93: e143. 2014\/12\/05. DOI: https:\/\/doi.org\/10.1097\/md.0000000000000143.","DOI":"10.1097\/md.0000000000000143"},{"key":"1888_CR38","unstructured":"Pierer M, Luttosch F, Baerwald C. Role of complement-inhibition in thrombotic microangiopathy (TMA) associated with systemic lupus erythematosus (SLE): a case report. Z Rheumatol. 2013;72."},{"key":"1888_CR39","doi-asserted-by":"publisher","unstructured":"Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011; 11: 2523\u20132527. 2011\/08\/13. DOI: https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03696.x.","DOI":"10.1111\/j.1600-6143.2011.03696.x"},{"key":"1888_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5582\/irdr.2014.01001","volume":"3","author":"BS Kaplan","year":"2014","unstructured":"Kaplan BS, Ruebner RL, Spinale JM, et al. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34\u201345. https:\/\/doi.org\/10.5582\/irdr.2014.01001.","journal-title":"Intractable Rare Dis Res"},{"key":"1888_CR41","doi-asserted-by":"publisher","unstructured":"Wang S, Wu M, Chiriboga L, et al. Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment. Semin Arthritis Rheum 2018; 48: 256\u2013262. 2018\/02\/06. DOI: https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.004.","DOI":"10.1016\/j.semarthrit.2018.01.004"},{"key":"1888_CR42","doi-asserted-by":"publisher","unstructured":"Menne J, Delmas Y, Fakhouri F, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol 2019; 20: 125. 2019\/04\/12. DOI: https:\/\/doi.org\/10.1186\/s12882-019-1314-1.","DOI":"10.1186\/s12882-019-1314-1"},{"key":"1888_CR43","doi-asserted-by":"publisher","unstructured":"Eculizumab - with \u00a3340,200 price tag - gets go ahead from NICE. The Pharmaceutical Journal, 7 February 2015, Vol 294, No 7848, online. https:\/\/doi.org\/10.1211\/PJ.2015.20067720.","DOI":"10.1211\/PJ.2015.20067720"},{"key":"1888_CR44","doi-asserted-by":"crossref","unstructured":"Park MH, Caselman N, Ulmer S, et al. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018, pp.2090-2094.","DOI":"10.1182\/bloodadvances.2018019596"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01888-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T19:21:12Z","timestamp":1624994472000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01888-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1888"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01888-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"26 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}